-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Reiterates Neutral on Intra-Cellular Therapies, Maintains $132 Price Target

Benzinga·04/02/2025 14:32:59
Listen to the news
Cantor Fitzgerald analyst Charles Duncan reiterates Intra-Cellular Therapies (NASDAQ:ITCI) with a Neutral and maintains $132 price target.